Skip to main content

Find a clinical trial

Find a clinical trial

Trial status
Trial Phase
Trial type
72 clinical trials grid list download
  • Titre Organe Phase Statut Crittères majeurs d'inclusion Contact
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiples phase 1 Ouvert any line, RECIST 1.1 Ahmad Hussein Awada
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiples phase 1/1b Fermé any line, RECIST 1.1 Philippe Aftimos
  • APHINITY A randomised multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. sein Fermé Non metastatic, operable HER2+ carcinoma of the breast Martine Piccart
  • APPALACHES A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES) sein phase 2 Ouvert Stage II or stage III, early invasive breast cancer. ER+/HER2- Lissandra Dal Lago
  • Ascent An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments sein phase 3 Fermé 3rd line metastatic Philippe Aftimos
  • AURORA BIG 14-01 AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer sein phase 3 Ouvert after one line, biopsy Philippe Aftimos
  • B PRECISE 01 Open-label, multicentre, phase Ib dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab +/- fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy sein phase 1/1b Ouvert HER+. Advanced or metastatic with PIK3CA mutation Philippe Aftimos
  • BAY 88-8223 / 16996 A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride Multiples phase 4 Fermé Subject was previously enrolled in a selected company-sponsored feeder trial, and has received at least 1 dose of radium-223 dichloride or placebo in the feeder trial. Géraldine Gebhart
  • BAY 88-8223 / 17096 A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases sein phase 2 Fermé *HER negative hormone receptor positive breast cancer* received at least one line of hormonal therapy in the metastatic setting
    *eligible for exemestane and everolimus
    * experienced no more than 2 skeletal related event (SRE)
    Géraldine Gebhart
  • BSMO 2014 01 A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negative breast cancer sein phase 2 Fermé TNBC Daphné Tkint de Roodenbeke
  • CA209358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors Multiples phase 1/2 Fermé ECOG 0 or 1 Ahmad Hussein Awada
  • CANFOUR An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Multiples phase 1/2 Ouvert Metastatic Christiane Jungels
  • DESIGN The DESIGN trial A randomised, Double-blind, placEbo-controlled Study to assess the effectIveness of pectoral nerves block (Pecs) after breast surGery on Piritramide coNsumption sein phase 3 Fermé Conservative or non-conservative breast surgery associated with axillary dissection Maurice Sosnowski
  • DS8201-A-U302 DS8201-A-U302 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer sein phase 3 Fermé HER2+. Metastatic/unresecable Andrea Gombos